Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Preferred Stock Liabilities (2016 - 2018)

Alaunos Therapeutics (TCRT) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $160.4 million as the latest value for Q3 2018.

  • For the quarter ending Q3 2018, Preferred Stock Liabilities rose 15.36% year-over-year to $160.4 million, compared with a TTM value of $160.4 million through Sep 2018, up 15.36%, and an annual FY2017 reading of $144.0 million, up 14.9% over the prior year.
  • Preferred Stock Liabilities was $160.4 million for Q3 2018 at Alaunos Therapeutics, up from $154.4 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $160.4 million in Q3 2018 and bottomed at $121.8 million in Q3 2016.
  • Average Preferred Stock Liabilities over 3 years is $139.8 million, with a median of $139.1 million recorded in 2017.
  • The sharpest move saw Preferred Stock Liabilities grew 14.16% in 2017, then increased 15.36% in 2018.
  • Year by year, Preferred Stock Liabilities stood at $125.3 million in 2016, then increased by 14.9% to $144.0 million in 2017, then rose by 11.42% to $160.4 million in 2018.
  • Business Quant data shows Preferred Stock Liabilities for TCRT at $160.4 million in Q3 2018, $154.4 million in Q2 2018, and $149.0 million in Q1 2018.